
The report indicates a rise in biotech funding and subsequent growth for pharma contract services.
Daria G. Husni is Assistant Editor for BioPharm International.
The report indicates a rise in biotech funding and subsequent growth for pharma contract services.
Wheeler plans to use the facility to bolster its mission in helping fledgling biotech innovators and startups accelerate their development at an equitable price.
Mirati’s focus on breakthrough cancer treatments will bolster Bristol Myers Squibb’s oncology portfolio.
Spinning off Sandoz allows Novartis to focus on the areas of cardiovascular, immunology, renal and metabolic, and oncology.
The BioIndustry Association reports that with a strong foundation in research and development in mRNA the United Kingdom will be a major player in this rapidly growing industry.
The Japanese biotech company plans to make good use of Orchard’s portfolio, furthering its goal of providing life-changing medical care through cell and gene therapy.
The program will allow sponsors of certain CBER and/or CDER-regulated products more frequent communication with FDA staff.
The prize was awarded jointly to Katalin Karikó and Drew Weissman for their groundbreaking discovery regarding modification of the bases in mRNA.
The contract is part of US Department of Health and Human Services’ ‘Project NextGen’ initiative, aimed at pushing forward new and stronger COVID-19 vaccines and therapies.
The tools, originally utilized during the COVID-19 pandemic, are now intended to work alongside FDA’s standard procedures.
The AstraZeneca rare disease group hopes to use these new gene therapy programs to bolster its work on genomic medicine.
As more novel therapy approvals trend towards biologics, it is important to take stock of what treatments are shaping the future of the market.
The new policy will require trading partners to supply, accept, and manage all documentation of product and ownership of prescription drugs electronically.
The updated vaccine will be ready to ship following a positive European Commission review.
This is the first biosimilar to Tysabri, an injection for adults with multiple sclerosis.
The patent grants Alterity 20 years of exclusivity over a new class of iron chaperone drug candidates.
The immunization, meant to protect infants aged six months or lower, is given to pregnant individuals at a gestation period of 32 to 36 weeks.
A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.
Novartis has completed its acquisition of biopharma company Chinook Therapeutics.
The guidance can help both applicants and manufacturers limit the mutagenic and carcinogenic potential of NDSRIs.
The program aims to aid submissions from external stakeholders and FDA staff.
The guidance document outlines recommendations to limit potential carcinogenic risk.
The damage to the facility, which produces 8% of US injectable drug consumption, should not significantly affect the current supply.
The framework is now expanded beyond COVID-19 vaccines and treatments.
The paper highlights the potential of AI in the medicinal product lifecycle and the approach that developers should take with it.
The new drug may help vulnerable children resist RSV in the coming fall and winter season.
The document’s recommendations outline what studies and reports are required for changes to cell and gene therapy manufacturing.
These recommendations will keep key antibiotics for respiratory infections available when they are needed most.